Abrégé

A divalent antigen for preventing respiratory syncytial virus infections, and the use thereof. On the basis of the F protein sequences of subtype strains RSVA and RSVB, new F divalent antigen sequences of subtypes A and B are respectively obtained by means of removing epitope sequences I and IV, which are specific to post-F, and part of epitope sequence III, which is shared by pre-F and post-F; and then the new F divalent antigen sequences of subtypes A and B are linked in series to form a new F divalent antigen dimer, which is kept in a pre-F conformation in vivo and in vitro, thereby stimulating the body to generate specific antibodies against a pre-F epitope that have a high neutralization activity. The divalent dimer antigen has the advantage of stimulating the body to generate more neutralizing antibodies and the advantage of high yield.

Classes IPC  ?

• C07K 14/135 - Virus respiratoire syncytial
• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 37/04 - Immunostimulants
• C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C07K 19/00 - Peptides hybrides

Abrégé

Provided are an African swine fever virus attenuated strain, a preparation method therefor, and a use thereof in preparation of drugs (such as vaccines) for preventing African swine fever virus infection. The African swine fever virus attenuated strain has deletion of A137R and CD2V genes or functional fragments thereof in a genome relative to a wild-type strain; compared with a wild-type virus strain, the African swine fever virus attenuated strain has greatly reduced virulence, can induce high-level humoral immune response against African swine fever virus, can protect experimental animals from attack by lethal doses of highly virulent strains of African swine fever virus, and thus has excellent application prospects in preventing African swine fever virus infection.

Classes IPC  ?

• C12N 7/04 - Inactivation ou atténuationProduction de parties élémentaires de virus
• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C12N 15/34 - Protéines de virus à ADN
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 9/22 - Ribonucléases
• A61K 39/12 - Antigènes viraux
• A61P 31/20 - Antiviraux pour le traitement des virus ADN

Abrégé

A beta-coronavirus (β-CoV) recombinant chimeric antigen, a preparation method therefor and a use thereof. The β-CoV recombinant chimeric antigen is a chimeric dimer antigen formed by linking an RBD fragment of S protein of a SARS-CoV-2 Omicron variant BA.1 subtype or BA.2 subtype and an RBD fragment of S protein of SARS-CoV in series, which can not only stimulate an organism to generate high-level neutralizing antibodies against a SARS-CoV-2 prototype strain and various variants and against SARS-CoV, but also stimulate the organism to generate high-level neutralizing antibodies against other SARS-related coronaviruses, so that the β-CoV recombinant chimeric antigen is expected to become an immunogen for broad-spectrum vaccines against β-CoVs, and has great clinical application prospects and industrial values.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Provided are an mRNA encoding a Zika virus antigen peptide, an mRNA construct encoding a Zika virus antigen peptide, a recombinant expression plasmid for producing the mRNA, an mRNA vaccine against Zika virus based on the mRNA and a preparation method for the mRNA vaccine. The mRNA vaccine against Zika virus can not only avoid induced generation of FL epitope antibodies so as to significantly reduce or eliminate the ADE effect, but also generate high-level neutralizing antibodies higher than those of other vaccine vector platforms so as to effectively prevent or treat Zika virus infectious diseases, and has better clinical application values and prospects.

Classes IPC  ?

• C12N 15/40 - Protéines de virus à ARN, p. ex. flavivirus
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• A61K 39/12 - Antigènes viraux
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The invention relates to an anti-coronavirus polypeptide as well as derivatives and application thereof, provides the anti-coronavirus polypeptide, and provides cholesterol-containing derivatives of the polypeptide on the basis of the anti-coronavirus polypeptide. Particularly, the original strain and the variant strain of the SARS-COV-2 have an unexpected inhibition effect, can be used for preparing medicines or vaccines for preventing or treating the new coronavirus, and have great prevention or treatment potential.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

A protein for preventing respiratory syncytial virus infection and a use thereof. On the basis of RSV F protein sequences, specific I and IV epitope sequences of post-F and common III epitope partial sequences of pre-F and post-F are removed to obtain new F antigen sequences; and the two new F antigen sequences are then connected in series to form a new F antigen dimer, and the new F antigen dimer is maintained in pre-F conformation in vivo and in vitro, thereby stimulating an organism to generate an antibody which is specific to a pre-F epitope and has high neutralizing activity. The dimer antigen has the advantages of stimulating an organism to generate more neutralizing antibodies and having a high yield.

Classes IPC  ?

• C07K 14/135 - Virus respiratoire syncytial
• C07K 19/00 - Peptides hybrides
• A61K 39/155 - Paramyxoviridae, p. ex. virus de para-influenza
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 37/04 - Immunostimulants
• C12N 15/45 - Paramyxoviridae, p. ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

Provided are a modified Pichia pastoris strain and a preparation method therefor, a recombinant Pichia pastoris engineered strain, based on the modified Pichia pastoris strain, expressing a SARS-CoV-2 antigen, a preparation method therefor, and a use thereof, and a method for preparing a SARS-CoV-2 recombinant protein vaccine. A modified Pichia pastoris expression vector can not only express and secrete recombinant proteins at a high level, but also enable the expressed recombinant proteins to retain a core glycosylation modification. Glycoproteins secreted thereby have good uniformity. The recombinant Pichia pastoris engineered strain, based on the Pichia pastoris expression vector, expressing the SARS-CoV-2 antigen can produce, in a highly efficient manner, high-quality RBD dimer antigens having uniform glycosylation. The produced RBD dimer antigens can be used as immunogens to induce the production of high-level neutralizing antibodies against a SARS-CoV-2 prototype strain and variants thereof.

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C07K 19/00 - Peptides hybrides
• C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12R 1/84 - Pichia

Abrégé

Provided are a class of polypeptides targeting protein degradation and an application thereof, the polypeptides can be any of the following a1)-a4): a1) polypeptides having amino acid sequences comprising an amino acid sequence shown in positions 15-24 of SEQ ID No. 3; a2) fusion polypeptides obtained by connecting a tag to the N-terminus and/or C-terminus of the polypeptides set forth in a1); a3) polypeptides having the same function obtained by substituting and/or deleting and/or adding one or more amino acid residues of the amino acid sequences set forth in a1); and a4) polypeptides having 80% or more identity with the amino acid sequences set forth in a1) and having the same function. Experiments have shown that the polypeptides provided can reduce the number of pathogens in citrus infected with the citrus greening disease, can promote the lysis of pathogens in citrus infected with the citrus greening disease, and eventually kill the pathogens. Said polypeptides have very good potential application values in preventing and controlling the citrus greening disease.

Classes IPC  ?

• C07K 4/00 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 38/00 - Préparations médicinales contenant des peptides
• C07K 4/12 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'animauxPeptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'humains

Abrégé

The present invention provides a bispecific antibody for a broad-spectrum novel coronavirus. The bispecific antibody of the present invention comprises a first targeting domain D1, which targets a first epitope of a SARS-CoV-2RBD domain; and a second targeting domain D2, which targets a second epitope of the SARS-CoV-2RBD domain. The bispecific antibody of the present invention has broad-spectrum neutralizing activity, can effectively neutralize SARS‐CoV‐2 and a variety of SARS‐CoV‐2 novel coronavirus variants having strong infectivity and high harmfulness, and therefore has great application value in prevention, treatment and/or detection of novel coronavirus infection.

Classes IPC  ?

• C07K 16/46 - Immunoglobulines hybrides
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

Provided are a cultivation method for an anti-yellow-shoot-disease plant and the use thereof. CsPUB21 can attenuate terpene-compound-based defensive responses of citrus by means of direct ubiquitination and degradation of CsMYC2 protein, while silencing the CsPUB21 gene can improve the resistance of citrus against pathogenic bacteria CLas and a propagation carrier thereof, Asian citrus psyllid. Further provided is a PUB21 dominant negative mutant CsPUB21DN, wherein over-expression of the CsPUB21DN can reduce the infection of the pathogenic bacteria CLas. In addition, manually replacing a key enzyme activity site, the 39th amino acid Cys (TGC), of the CsPUB21 in an infected plant with Ala (GCC) by means of prime editing technique can effectively reduce the CLas concentration in leaves of the infected plant. The present invention provides a gene resource capable of effectively resisting the replication and propagation of pathogenic bacteria of yellow shoot disease, which has very high application values in the field of controlling the yellow shoot disease.

Classes IPC  ?

• C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• C12N 15/29 - Gènes codant pour des protéines végétales, p. ex. thaumatine
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• A01H 5/00 - Angiospermes, c.-à-d. plantes à fleurs, caractérisées par leurs parties végétalesAngiospermes caractérisées autrement que par leur taxonomie botanique
• A01H 6/78 - Rutaceae, p. ex. citron ou citron vert

Abrégé

Provided in the present disclosure is an antibody or an antigen-binding fragment thereof that binds to the respiratory syncytial virus F protein. Further provided in the present disclosure is the use of the antibody or the antigen-binding fragment thereof in the preparation of a drug for the treatment and/or prevention of RSV infections.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Abrégé

Provided are a recombinant chimeric antigen for a poxvirus, in particular for a Mpoxvirus, a subunit vaccine comprising the recombinant chimeric antigen, and a use thereof. The recombinant chimeric antigen of the present application comprises two immunogens arranged in a specific manner: a Mpoxvirus A35 protein or an antigenic fragment thereof or derivative peptides of same, and a Mpoxvirus M1 protein or an antigenic fragment thereof or derivative peptides of same, and can excite an immune response to two infectious virus particles of intracellular mature virus (IMV) particles and extracellular enveloped virus (EEV) particles.

Classes IPC  ?

• C07K 14/065 - Poxviridae, p. ex. avipoxvirus
• A61K 39/275 - Poxviridae, p. ex. Avipoxvirus
• A61P 31/12 - Antiviraux
• C12N 15/39 - Poxviridae, p. ex. virus de la vaccine, virus de la variole
• C07K 19/00 - Peptides hybrides
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61P 31/20 - Antiviraux pour le traitement des virus ADN

Abrégé

The present invention provides a combination of an inositol phosphorylceramide synthetase inhibitor and amphotericin B, and a use thereof. The use of the combination comprises the preparation of a pharmaceutical composition comprising an inositol phosphorylceramide synthetase inhibitor and amphotericin B or salts thereof. Inositol phosphorylceramide is an important and conservative component of a fungal plasma membrane. According to the pharmaceutical composition of embodiments of the present invention, due to the addition of the inositol phosphorylceramide synthetase inhibitor, the inositol phosphorylceramide synthetase inhibitor and the amphotericin B interact with each other, so that the inhibition capability of the inositol phosphorylceramide synthetase inhibitor on the synthesis of cryptococcal inositol phosphorylceramide is enhanced, the dose of the amphotericin B is effectively reduced, the half-life period of the amphotericin B is prolonged, and the adverse effects of the amphotericin B are reduced. Compared with a clinically used combination of 5-fluorocytosine and amphotericin B, the pharmaceutical composition has a better sterilization effect and better safety.

Classes IPC  ?

• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 38/15 - DepsipeptidesLeurs dérivés
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61P 31/04 - Agents antibactériens

Abrégé

Provided are a polynucleotide encoding a chimeric or mixed antigen of poxvirus multiple immunogens, a related nucleic acid product thereof, and the use thereof in the preparation of a vaccine for preventing and/or treating poxvirus (in particular monkeypox virus) infection. The chimeric or mixed antigen of the poxvirus multiple immunogens encoded by the polynucleotide comprises two immunogens: a monkeypox virus A35R protein or an antigenic fragment thereof (or an appropriate variant thereof) and a monkeypox virus M1R protein or an antigenic fragment thereof (or an appropriate variant thereof). The immunogen components of the chimeric or mixed nucleic acid vaccine based on the polynucleotide are clear, and the chimeric or mixed nucleic acid vaccine can efficiently stimulate specific immune responses (for example, generating a protective antibody) against poxvirus (in particular monkeypox virus), can be used for preventing and/or treating poxvirus (in particular monkeypox virus), and has high clinical application prospects.

Classes IPC  ?

• C12N 15/39 - Poxviridae, p. ex. virus de la vaccine, virus de la variole
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 39/275 - Poxviridae, p. ex. Avipoxvirus
• A61K 39/285 - Virus de la vaccine ou virus de la variole
• A61P 31/20 - Antiviraux pour le traitement des virus ADN

Abrégé

A mpoxvirus recombinant chimeric antigen, an immunogenic composition, and a use of the recombinant chimeric antigen. The recombinant chimeric antigen comprising a mpoxvirus A35 protein and a mpoxvirus M1 protein can stimulate an immune response against two infectious virus particles, i.e., intracellular mature virus (IMV) particles and extracellular enveloped virus (EEV) particles, thereby efficiently stimulating a specific immunoprotective effect against mpoxvirus.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 39/275 - Poxviridae, p. ex. Avipoxvirus
• A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
• A61P 31/20 - Antiviraux pour le traitement des virus ADN

Abrégé

The present application relates to a polypeptide for preventing or treating a novel coronavirus and an application thereof. The polypeptide is P3 polypeptide and any one of P3-1 polypeptide, P3-2 polypeptide, P3-3 polypeptide, P3-4 polypeptide, and P3-5 polypeptide derived from the P3 polypeptide. The amino acid sequences of the P3 polypeptide, the P3-1 polypeptide, the P3-2 polypeptide, the P3-3 polypeptide, the P3-4 polypeptide, and the P3-5 polypeptide are respectively shown in SEQ ID NOs: 1-6. The polypeptide of the present application has a strong inhibitory effect on original strains and a plurality of variant strains of the novel coronavirus, and can be used for preparing a drug or a vaccine for preventing and/or treating diseases caused by the novel coronavirus. The polypeptide is expected to also have the potential of preventing and/or treating new variant strains appearing in the future and sarbecovirus.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C12N 15/86 - Vecteurs viraux

Abrégé

Provided are a type I-F2 CRISPR-Cas system for regulating and controlling eukaryotic cell gene transcription, and a use thereof, relating to the technical field of genetic engineering. The technical problem to be solved is: how to realize efficient transcription regulation and control by a simplified CRISPR-Cas system in eukaryotic cells. In order to solve the technical problem, the present invention provides a type I-F2 CRISPR-Cas system for regulating and controlling eukaryotic cell gene transcription, comprising a fusion protein formed by Cas7, a transcriptional factor, Cas6 and Cas5, and crRNA targeting a target gene. The selected type I-F2 CRISPR-Cas system can realize transcription regulation and control of a target gene in eukaryotic cells by coupling a transcriptional factor to a Cas protein.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 9/22 - Ribonucléases
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/65 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression utilisant des marqueurs
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome

Abrégé

The present application provides a monoclonal antibody or an antigen-binding fragment thereof that specifically binds to the RBD domain of SARS-CoV or SARS-CoV-2, a preparation method therefor, and the use thereof. The monoclonal antibody or the antigen-binding fragment thereof can bind to the RBD antigen of SARS-CoV or SARS-CoV-2 with a high affinity, and can neutralize SARS-CoV and SARS-CoV-2 prototype strains and a series of SARS-CoV and SARS-CoV-2 mutant strains with a relatively high neutralization activity, thereby inhibiting the infections caused by the above strains. Therefore, the monoclonal antibody or the antigen-binding fragment thereof has great potential application value in clinical treatment, prevention and/or detection of infections caused by SARS-CoV and SARS-CoV-2 prototype strains and SARS-CoV and SARS-CoV-2 mutant strains.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present application relates to a multi-immunogen chimeric or mixed antigen against poxviruses (particularly monkeypox viruses), a related product thereof, a preparation method therefor and the use thereof. The chimeric or mixed antigen of the present application comprises three immunogens: (1) a monkeypox virus A35R protein or an antigenic fragment thereof (or a derived peptide fragment thereof); (2) a monkeypox virus M1R protein or an antigenic fragment thereof (or a derived peptide fragment thereof); and (3) a monkeypox virus B6R protein or an antigenic fragment thereof (or a derived peptide fragment thereof). The chimeric or mixed antigen of the present application can elicit an immune response against two infectious virus particles of intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV), thereby efficiently eliciting a specific immune protection effect against monkeypox viruses; in addition, the poxvirus vaccine of the present application also has good safety, rapid responsiveness and productivity support, and has great clinical application prospects.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C07K 14/065 - Poxviridae, p. ex. avipoxvirus
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/39 - Poxviridae, p. ex. virus de la vaccine, virus de la variole
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 39/275 - Poxviridae, p. ex. Avipoxvirus
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 31/20 - Antiviraux pour le traitement des virus ADN

Abrégé

The present application relates to a monoclonal antibody or an antigen-binding fragment thereof that specifically binds to the SARS-CoV-2 RBD domain, and a related product thereof, a preparation method therefor and the use thereof. The monoclonal antibody or antigen-binding fragment thereof of the present application can bind to the SARS-CoV-2 RBD antigen with a high affinity, and can neutralize the SARS-CoV-2 prototype strain and a series of variant strains thereof with a high neutralizing activity, thereby inhibiting the infection caused thereby. Therefore, the monoclonal antibody has a great potential application value in the clinical treatment, prevention and/or detection of infections caused by the SARS-CoV-2 prototype strain and variant strains thereof.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Abrégé

Provided in the present disclosure are a Zika/dengue vaccine and its application thereof. The present disclosure introduces a mutation into the E-protein FL fusion region of the Zika virus or dengue virus. Antigens with said mutations are unable to bind to antibodies that causes ADE. After immunization with the vaccine of the present disclosure acquired from the said antigens, production of FL epitope-induced antibodies can be prevented, thereby reducing or eliminating the ADE effect.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/86 - Vecteurs viraux

Abrégé

The present invention relates to the field of gene technology for disease prevention and control. The present invention provides a method for preparing a biocontrol engineering microorganism using Trichoderma harzianum as a dsRNA vector. The method comprises the following steps: determining a target gene according to a pathogenic fungus; taking the target gene as an arm sequence and the intron sequence of a Verticillium dahliae endogenous gene VdTublin as a center, and ligating two identical arm sequences to the two ends of the intron forward and reversely, respectively, so as to construct a target sequence; and transferring the target sequence into Trichoderma harzianum by means of ATMT to give the Trichoderma harzianum engineering microorganism. The engineering strain obtained by the present invention has a relatively good effect in inhibiting the growth and pathogenicity of the corresponding fungi.

Classes IPC  ?

• C12N 15/80 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons
• C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
• C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger

Abrégé

The present invention relates to the field of genetic engineering, and particularly, to a novel sterilization method for accurately and efficiently killing drug-resistant bacteria by means of the combination of CRISPR and a conjugated toxin-antitoxin (TA) element thereto. By utilizing a guard RNA element CreTA of CRISPR to improve the stability of the CRISPR-Cas element in the process of killing the drug-resistant bacteria, the present invention achieves dual sterilization effects of CRISPR and TA, thus effectively improving the efficiency of the CRISPR sterilization technology in practical applications.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 9/22 - Ribonucléases
• C12N 15/31 - Gènes codant pour des protéines microbiennes, p. ex. entérotoxines
• C12N 15/65 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression utilisant des marqueurs
• C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 31/04 - Agents antibactériens
• C12R 1/01 - Bactéries ou actinomycètes
• C12R 1/19 - Escherichia coli

Abrégé

Disclosed are a chimeric compound for degrading cyclophilin A, a preparation method therefor, and use thereof. The structural formula of the chimeric compound is represented by formula I. The compound represented by formula I provided by the present invention can be used for preventing and/or treating CypA-mediated diseases, such as CypA-mediated inflammation, autoimmune diseases and/or tumors. The present invention further provides a pharmaceutical composition comprising the compound represented by formula I as an active ingredient and at least one pharmaceutically acceptable carrier, excipient and/or diluent. The compound represented by formula I provided by the present invention can target and degrade the CypA protein, and thus can be used for preparing a drug for treating inflammation, autoimmune diseases, tumors and other related diseases. The compound represented by formula I of the present invention has the function of significantly inhibiting virus-induced pneumonia, rheumatoid arthritis and lung cancer cell migration and infiltration.

Classes IPC  ?

• C07K 5/062 - Dipeptides la chaîne latérale du premier amino-acide étant acyclique, p. ex. Gly, Ala
• C07K 1/12 - Procédés généraux de préparation de peptides par hydrolyse
• C07K 1/02 - Procédés généraux de préparation de peptides en solution
• A61K 38/05 - Dipeptides
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux
• A61P 37/02 - Immunomodulateurs

Abrégé

A novel coronavirus heterologous trimerized chimeric antigen peptide, a polynucleotide encoding same or a nucleic acid product related to the polynucleotide, a vaccine or an immunogenic composition based on the antigen peptide or the polynucleotide, and use of these products in a novel coronavirus vaccine.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/86 - Vecteurs viraux
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present disclosure provides two specific T cell receptors targeting a G12V or G12C mutant epitope of a KRAS gene, and an anti-tumor use thereof. Each of the two T cell receptors consists of an α peptide chain and a β peptide chain. Further provided are an antigen binding fragment of the T cell receptors, a nucleic acid encoding the T cell receptors or an antigen binding fragment thereof, a vector comprising the nucleic acid, and a host cell comprising the vector. Further provided is a method for preparing a specific T cell receptor for a KRAS G12V mutation or an antigen-binding fragment thereof. The specific T cell receptor and antigen-binding fragment thereof can be used as an immune activator to stimulate an immune response of an organism, thereby generating an effect against tumors and other diseases.

Classes IPC  ?

• C07K 14/725 - Récepteurs de lymphocytes-T
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61P 35/00 - Agents anticancéreux

Abrégé

Disclosed in the present invention are a recombinant chimeric antigen of the prototype strain and Delta and Omicron variant strains of SARS-CoV-2, a preparation method therefor, and the use thereof. The recombinant chimeric antigen is formed by directly tandemly linking, or tandemly linking by an appropriate linking sequence, the amino acid sequences or derived sequences thereof from the RBDs of the prototype strain of and the Delta and Omicron variant strains of SARS-CoV-2. Compared with an RBD homotrimer of the SARS-CoV-2 prototype strain, the recombinant chimeric antigen has higher immunogenicity and can efficiently activate a broadly protective antibody.

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C07K 19/00 - Peptides hybrides
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

A polynucleotide, a related product thereof, a use thereof in the preparation of a novel coronavirus vaccine, and a chimeric nucleic acid vaccine or immunogenic composition based on the polynucleotide; the polynucleotide encodes a recombinant chimeric antigen directly series-connecting or connecting via a linker: a novel coronavirus prototype S protein RBD domain to a Beta variant S protein RBD domain, or a Delta variant S protein RBD domain to a Beta variant S protein RBD domain, or a Delta variant S protein RBD domain to an Omicron variant S protein RBD domain; the chimeric nucleic acid vaccine based on the polynucleotide can provide relatively strong immune protection efficacy for various novel coronavirus strains, and when sequential immunization is performed with other types of vaccines, can induce a significant increase to immune response level for various strains of the novel coronavirus (i.e., broad-spectrum).

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present application relates to a chimeric antigen of SARS-CoV-2 Delta and Omicron variants, and a preparation method therefor and the use thereof. The recombinant antigen of the present application is formed by: (1) a specific amino acid sequence from a SARS-CoV-2 Delta variant RBD protein; and (2) a specific amino acid sequence from a SARS-CoV-2 Omicron variant RBD protein by means of an appropriate linking sequence or direct linking in series. Compared to an RBD homodimer of an original SARS-CoV-2 strain or a variant thereof, the recombinant antigen of the present application can activate broad-spectrum protective antibodies more efficiently, and can also achieve a good prevention or treatment effect on the original strain and existing various variants.

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C07K 19/00 - Peptides hybrides
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens

Abrégé

Provided are a construct (comprising a multivalent nano-antibody and a nano-antibody fusion protein) based on a nano-antibody R14 specifically binding to SARS-CoV-2 RBD, a related product thereof, and a use thereof. The construct (comprising a multivalent nano-antibody and a nano-antibody fusion protein) based on the nano-antibody R14 specifically binding to SARS-CoV -2 RBD can effectively inhibit SARS-CoV -2 infection and variant strain infection thereof, be administered as a nebulized drug, can directly reach the lungs, takes effect quickly, has a long half-life period, and provides a more effective treatment strategy for clinically preventing or treating novel coronavirus and variant strain infection thereof.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Provided are a construct (comprising a multivalent nano-antibody and a nano-antibody fusion protein) based on a nano-antibody R14 specifically binding to SARS-CoV-2 RBD, a related product thereof, and a use thereof. The construct (comprising a multivalent nano-antibody and a nano-antibody fusion protein) based on the nano-antibody R14 specifically binding to SARS-CoV -2 RBD can effectively inhibit SARS-CoV -2 infection and variant strain infection thereof, be administered as a nebulized drug, can directly reach the lungs, takes effect quickly, has a long half-life period, and provides a more effective treatment strategy for clinically preventing or treating novel coronavirus and variant strain infection thereof.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Provided are a construct (comprising a multivalent nano-antibody and a nano-antibody fusion protein) based on a nano-antibody S43 that specifically binds to SARS-CoV-2 RBD, a related product of the construct, and an application thereof. The construct can effectively inhibit SARS-CoV-2 infection and variant strain infection of SARS-CoV-2, can be administrated by means of nebulization, can directly reach the lung, takes effect quickly, is long in half-life, and provides a more effective treatment strategy for clinical prevention or treatment of novel coronavirus and variant strain infection thereof.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C07K 19/00 - Peptides hybrides
• C12N 15/13 - Immunoglobulines
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Provided are a construct (comprising a multivalent nanobody and a nanobody fusion protein) based on a nanobody S43 which specifically binds to SARS-CoV-2 RBD, and a related product and application thereof; the construct based on a nanobody S43 which specifically binds to the SARS-CoV-2 RBD (comprising the multivalent nanobody and the nanobody fusion protein) can effectively inhibit SARS-CoV-2 infection and variant strain infections thereof, can be administered as a nebulized medicine, can directly reach the lungs, takes effect quickly, has a long half-life, and provides a more effective treatment strategy for the clinical prevention or treatment of novel coronavirus and variant strain infection thereof.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C07K 19/00 - Peptides hybrides
• C12N 15/13 - Immunoglobulines
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to the field of microorganisms, in particular to a method for producing vitamin B5 by means of high-activity aspartate decarboxylase. L-aspartate α-decarboxylase (PanD) derived from Bacillus licheniformis is screened, and the activity of producing β-alanine by means of catalysis is obviously higher than that of PanD derived from others. The engineering bacteria for producing vitamin B5 by means of fermentation are constructed by using PanD derived from B.licheniformis, and a β-alanine metabolism bottleneck of biosynthesizing vitamin B5 is relieved. Compared with a high-pollution chemical method for producing vitamin B5, the biological method for producing vitamin B5 has advantages such as renewable raw materials, easy disposal and resource utilization of waste slag, waste water and waste gas, thus can be used for industrial production of vitamin B5 in practice, and has important use value.

Classes IPC  ?

• C12N 15/60 - Lyases (4)
• C12N 9/88 - Lyases (4.)
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12P 13/02 - Amides, p. ex. chloramphénicol

Abrégé

Escherichia coli for expressing aspartate dehydrogenase gene (aspDH) and a method for using same for fermentation production of vitamin B5 (VB5). By comparing the fermentation yield of VB5, it is found that overexpressing the aspDH gene has the best effect. Compared with a high-pollution chemical method for producing vitamin B5, the biological method for producing the vitamin B5 has the advantages such as regenerable raw materials and easy treatment and recyclability of waste residues, wastewater and waste gas, and therefore can be used for industrial production of vitamin B5 in practice and has important application value.

Classes IPC  ?

• C12N 9/06 - Oxydoréductases (1.), p. ex. luciférase agissant sur des composés contenant de l'azote comme donneurs (1.4, 1.5, 1.7)
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12P 13/02 - Amides, p. ex. chloramphénicol

Abrégé

The present invention relates to a humanized antibody against broad-spectrum novel coronavirus and the use thereof. Conserved targets are quickly focused on by using a prototype strain RBD and Beta strain RBD antigen successive screening mode, and a fully humanized antibody that binds to different epitopes of RBD and can achieve broad-spectrum neutralization of VOC is successfully isolated in vitro. The IMCAS-123 antibody has affinities to a prototype strain, Alpha, Beta, Delta and Omicron that reach the nM level, an ability to neutralize pseudoviruses of the highly transmissible Omicron mutant strain that reaches 0.04 ug/ml, and is currently the only reported antibody that can neutralize all three of the Omicron escape strains BA.1, BA.2 and BA.3.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention discloses T-cell receptor of HLA-A11-restricted hepatitis B virus HBc 141-151 epitope peptide and applications thereof. The T cell receptor comprises an α chain and β chain; the α chain comprises three complementarity determining regions with amino acid sequences shown in positions 48 to 53, positions 71 to 77 and positions 112 to 121 of SEQ ID NO. 2, respectively; the β chain comprises three complementarity determining regions with amino acid sequences shown in positions 46 to 50, positions 68 to 73 and positions 111 to 122 of SEQ ID NO. 4, respectively. Experiments demonstrated that the T cell receptor exhibits both HBV polypeptide epitope-dependent activation and proliferation ability and also exhibits an ability to kill target cells both in vivo and in vitro.

Classes IPC  ?

• C07K 14/725 - Récepteurs de lymphocytes-T
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/20 - Antiviraux pour le traitement des virus ADN
• C12N 15/86 - Vecteurs viraux

Abrégé

Agrobacterium tumefaciens; and 3) transferring DNA containing Sfp and bpsA into a plant. The blue flowers produced by the present invention have various characteristics of natural flowers, being fresh, flower-scented, non-color-fading, and non-toxic. The transgene-encoded enzyme and the produced indigo are not in the vacuole and are not affected by the low pH of the plant vacuole, thereby resulting in a pure blue color. The precursor of the blue matter, i.e., the substrate of the enzyme, is glutamine, which is abundant in plants. The enzyme catalysis reaction comprises a single step, and the transgenic transformation can be carried out on natural white flowers.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C12N 9/88 - Lyases (4.)

Abrégé

Provided is an anti-coronavirus polypeptide, and on this basis, cholesterol-containing derivatives of the polypeptide are provided. These polypeptide derivatives yield an unexpected inhibitory effect on coronaviruses, and in particular prototype strains and variant strains of SARS-CoV-2, can be used for preparing a drug or vaccine for preventing or treating novel coronavirus, and has a great prevention or treatment potential.

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention belongs to the technical field of transmission electron microscopes. The present invention provides a transfer-type high-throughput ultrathin section staining instrument, comprising: a supporting platform; a supporting column which is located at the center position of the supporting platform and is fixed to the supporting platform; a bottle cap platform, the center position of which is fixed to the other end of the supporting column; and a rinsing pool, a staining bottle A and a staining bottle B which are fixed on the supporting platform and around the supporting column. The device provided by the present invention can be used for carrying out automatic operations of dye liquor staining, rinsing, air drying, re-dye liquor staining, rinsing and air drying on batch grids inserted on a grid frame, such that the working efficiency is improved, and the dye liquor is saved.

Classes IPC  ?

• G01N 1/31 - Appareils à cet effet
• G01N 23/04 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau et formant des images des matériaux
• G01N 23/20008 - Détails de construction des appareils d’analyse, p. ex. caractérisés par la source de rayons X, le détecteur ou le système optique à rayons XLeurs accessoiresPréparation d’échantillons à cet effet
• G01N 23/20058 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la diffraction de la radiation par les matériaux, p. ex. pour rechercher la structure cristallineRecherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la diffusion de la radiation par les matériaux, p. ex. pour rechercher les matériaux non cristallinsRecherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la réflexion de la radiation par les matériaux en mesurant la diffraction des électrons, p. ex. la diffraction d’électrons lents [LEED] ou la diffraction d’électrons de haute énergie en incidence rasante [RHEED]

Abrégé

Provided is a mutant of CRISPR nuclease FnCpf1. Compared with wild-type FnCpf1, the CRISPR nuclease FnCpf1 has the following mutations: K671R/E566V/D751G/N508H/N637S, K671R/E566V/D751G/F570L/N634D/R755K, K671R/E566V/D751G/S518G/K639R, K671R/E566V/D751G/F570L/E686D, K671R/E566V/D751G/K613N/N637S/N534K/G664V, K671R/E566V/D751G/K613N/F570L/G664S/N637Y, K671R/E566V/D751G/K613N/Y724C/F570L, or K671R/E566V/D751G/K613N/Y724C/F570L/R690I/L662I. The coding gene of the mutant has higher editing efficiency and wider editing range than the wild-type FnCpf1.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli

Abrégé

Provided are an alpaca-derived nanobody that binds to SARS-CoV-2 RBD and the use thereof. The nanobody can effectively inhibit infection with the SARS-CoV-2 pseudovirus, and can be used for preventing, treating and/or detecting SARS-CoV-2 infections.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Provided are an alpaca-derived nanobody combined with a SARS-CoV-2 RBD or an antigen-binding fragment thereof, and an application thereof. The nanobody may effectively inhibit SARS-CoV-2 pseudovirus infections, and may be used for the prevention, treatment and/or detection of SARS-CoV-2 infection.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Provided in the present invention are a humanized monoclonal antibody for the 2019 novel coronavirus (2019-nCOV) and the use thereof. The antibody is capable of specifically binding with a receptor binding domain (RBD) of 2019-nCOV and blocking the binding between the RBD of 2019-nCOV and ACE2, and furthermore inhibiting the infection caused by 2019-nCOV.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to a beta coronavirus heteromultimeric antigen, and a preparation method therefor and the use thereof. The beta coronavirus heteromultimeric antigen has an amino acid sequence comprising a plurality of monomers from a beta coronavirus that are connected to each other, wherein each monomer from the beta coronavirus is a partial amino acid sequence or a whole amino acid sequence of a receptor binding region of a beta coronavirus spike protein; the number of the monomers is an integer greater than or equal to three; and the plurality of monomers of the beta coronavirus heteromultimeric antigen comprise monomers from two heterologous beta coronaviruses or monomers from at least three heterogenous beta coronaviruses. The beta coronavirus RBD multimer can be stably expressed, and can induce a strong immune response against various beta coronaviruses after mice are immunized, so that only one antigen protein can achieve the immune effect of a multivalent vaccine.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire

Abrégé

The present application relates to a polypeptide for preventing or treating a novel coronavirus and an application thereof. The polypeptide is P3 polypeptide and at least one of P3-1 polypeptide, P3-2 polypeptide, P3-3 polypeptide, P3-4 polypeptide, and P3-5 polypeptide derived from the P3 polypeptide. The amino acid sequences of the P3 polypeptide, the P3-1 polypeptide, the P3-2 polypeptide, the P3-3 polypeptide, the P3-4 polypeptide, and the P3-5 polypeptide are respectively as shown in SEQ ID NOs: 1-6. The polypeptide of the present application has a strong inhibitory effect on original strains and a plurality of variant strains of the novel coronavirus, and can be used for preparing a drug or a vaccine for preventing and/or treating diseases caused by the novel coronavirus. The polypeptide is expected to also have the potential of preventing and/or treating new variant strains appearing in the future and sarbecovirus.

Classes IPC  ?

• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

A method for improving the production of Streptomyces polyketide compounds is provided. The method greatly improves the capability of the Streptomyces polyketide compounds by strengthening a triacylglycerol decomposition pathway in Streptomyces during the stationary phase. A method for switching the primary metabolism of Streptomyces to the secondary metabolism, Streptomyces producing polyketide compounds, and use thereof are also provided.

Classes IPC  ?

• C12P 13/00 - Préparation de composés organiques contenant de l'azote
• C12N 15/01 - Préparation de mutants sans introduction de matériel génétique étrangerProcédés de criblage à cet effet
• C12N 1/20 - BactériesLeurs milieux de culture
• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C12N 9/10 - Transférases (2.)
• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
• C12P 17/16 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles
• C12P 17/18 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles condensés entre eux ou condensés avec un système carbocyclique commun, p. ex. rifamycine

Abrégé

Provided in the present disclosure is an antibody or an antigen-binding fragment thereof that binds to the respiratory syncytial virus F protein. Further provided in the present disclosure is the use of the antibody or the antigen-binding fragment thereof in the preparation of a drug for the treatment and/or prevention of RSV infections.

Classes IPC  ?

• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux

Abrégé

An application of a branched-chain α-ketoacid dehydrogenase complex in preparation of malonyl coenzyme A. A method for preparing malonyl-CoA using a branched-chain α-ketoacid dehydrogenase complex, the method comprising introducing a gene encoding a branched-chain α-ketoacid dehydrogenase complex into a biological cell strain to obtain a recombinant cell strain capable of expressing the gene encoding the branched-chain α-ketoacid dehydrogenase complex; culturing the recombinant cell strain to prepare malonyl-CoA; the branched-chain α-ketoacid dehydrogenase complex is the following M1) or M2): M1) a set of proteins consisting of a bkdF protein, a bkdG protein, a bkdH protein and a lpdA1 protein; M2) a set of proteins consisting of a bkdA protein, a bkdB protein, a bkdC protein and the lpdA1 protein. Experimental results show that by using the branched-chain α-ketoacid dehydrogenase complex, not only malonyl-CoA can be prepared, but also a target product using malonyl-CoA as an intermediate product can further be prepared.

Classes IPC  ?

• C12P 19/32 - Nucléotides avec un système cyclique condensé, contenant un cycle à six chaînons, comportant deux atomes d'azote dans le même cycle, p. ex. nucléotides puriques, dinucléotide de la nicotinamide-adénine
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/20 - BactériesLeurs milieux de culture
• C12N 9/10 - Transférases (2.)
• C12P 7/22 - Préparation de composés organiques contenant de l'oxygène contenant un groupe hydroxyle aromatiques

Abrégé

The embodiments of the present disclosure relate to antigens of β-coronaviruses, preparation methods and uses thereof. The amino acid sequence of the antigen of the β-coronavirus includes an amino acid sequence arranged in a (A-B)-(A-B) pattern or an amino acid sequence arranged in a (A-B)-C-(A-B) pattern or an amino acid sequence arranged in a (A-B)-(A-B′) pattern or an amino acid sequence arranged in a (A-B)-C-(A-B′) pattern. The antigen of the β-coronavirus has a single-chain dimer structure. A single-chain dirtier expressed according to examples of the present disclosure is stable in content and has excellent immunogenicity as an antigen of a β-coronavirus, and a vaccine prepared by using the single-chain dimer as an antigen of a β-coronavirus can elicit high-titer neutralizing antibodies in mice.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus

Abrégé

The present application relates to a novel coronavirus multivalent antigen, and a preparation method therefor and an application thereof. An amino acid sequence of the novel coronavirus antigen comprises: an amino acid sequence arranged in an (A-B)-(A-B') pattern or an amino acid sequence arranged in an (A-B)-C-(A-B') pattern, wherein A-B represents a partial amino acid sequence or a full-length amino acid sequence of a receptor binding domain (RBD) of a surface spike protein of the novel coronavirus, C represents a linking amino acid sequence, and A-B' represents an amino acid sequence obtained by substituting the amino acid sequence of A-B with one or more amino acids in K417N, E484K or N501Y. Compared with a tandem repeat dimer of two original strain RBD proteins, the novel coronavirus multivalent antigen of the present application can activate a broad-spectrum protective antibody, and has a good preventive effect on both the original strain and the current epidemic strain.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques

Abrégé

The present disclosure discloses a method for inhibiting formation of a biofilm of bacteria. Specifically, the method may include treating the bacteria with an effective amount of a coumarin-chalcone compound. While inhibiting the formation of the biofilm of the bacteria, the effective amount of the coumarin-chalcone compound may reduce virulences of the bacteria and enhance a susceptibility of the bacteria to an antibiotic when applied in combination with the antibiotic. The present disclosure further discloses a composition including an effective amount of the coumarin-chalcone compound. The composition may be used to inhibit the formation of the biofilm of bacteria. The composition may also include an antibiotic, a minimal inhibitory concentration and a minimal biofilm eliminate concentration of which are reduced when the composition is used.

Classes IPC  ?

• A01N 35/06 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant deux liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. un radical aldéhyde contenant des groupes cétone ou thiocétone faisant partie d'un cycle, p. ex. cyclohexanone, quinoneLeurs dérivés, p. ex. cétals

Abrégé

Provided are a β-coronavirus multimeric antigen, a preparation method therefor and an application thereof, the amino acid sequence of the β-coronavirus multimeric antigen comprising: some amino acid sequences or all amino acid sequences of receptor-binding domains (RBDs) of a plurality of spike proteins of a β-coronavirus, the spike proteins directly forming a series connection or being in series by connecting to amino acid sequences, the some amino acid sequences or all amino acid sequences of the RBDs of the serially connected spike proteins being derived from the same β-coronavirus, and the plurality being an integer≥3. A SARS‑CoV‑2 RBD multimer may be stably expressed, and an immune response may be strongly induced after immunizing mice; in addition, a neutralizing antibody titer produced by the induced mice is significantly different from that of a SARS‑CoV‑2 RBD dimer.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention provides two specific T cell receptors targeting G12V or G12C mutation epitopes of a KRAS gene, and an antitumor use. The two T cell receptors respectively consist of peptide chains ? and ?. Further provided are an antigen binding fragment of the T cell receptors, a nucleic acid encoding the antigen binding fragment, a vector comprising the nucleic acid, and a host cell comprising the vector. Further provided is a method for preparing a G12V mutation specific T cell receptor of KRAS or an antigen binding fragment thereof. The specific T cell receptor and the antigen binding fragment thereof can be used as immune effect activators to stimulate the immune response of a body, thereby generating the action effect of resisting tumors and other diseases.

Classes IPC  ?

• C07K 14/725 - Récepteurs de lymphocytes-T

Abrégé

The present invention provides two specific T cell receptors targeting G12V or G12C mutation epitopes of a KRAS gene, and an antitumor use. The two T cell receptors respectively consist of peptide chains α and β. Further provided are an antigen binding fragment of the T cell receptors, a nucleic acid encoding the antigen binding fragment, a vector comprising the nucleic acid, and a host cell comprising the vector. Further provided is a method for preparing a G12V mutation specific T cell receptor of KRAS or an antigen binding fragment thereof. The specific T cell receptor and the antigen binding fragment thereof can be used as immune effect activators to stimulate the immune response of a body, thereby generating the action effect of resisting tumors and other diseases.

Classes IPC  ?

• C07K 14/725 - Récepteurs de lymphocytes-T
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/867 - Vecteurs rétroviraux
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61P 35/00 - Agents anticancéreux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Provided is a mutant of CRISPR nuclease FnCpf1. Compared with wild-type FnCpf1, the CRISPR nuclease FnCpf1 has the following mutations: K671R/E566V/D751G/N508H/N637S, K671R/E566V/D751G/F570L/N634D/R755K, K671R/E566V/D751G/S518G/K639R, K671R/E566V/D751G/F570L/E686D, K671R/E566V/D751G/K613N/N637S/N534K/G664V, K671R/E566V/D751G/K613N/F570L/G664S/N637Y, K671R/E566V/D751G/K613N/Y724C/F570L, or K671R/E566V/D751G/K613N/Y724C/F570L/R690I/L662I. The coding gene of the mutant has higher editing efficiency and wider editing range than the wild-type FnCpf1.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• C12N 15/55 - Hydrolases (3)
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12R 1/19 - Escherichia coli

Abrégé

A nanoparticle comprises water-insoluble polymer matrix and an indicator constituent(s), wherein the indicator constituent(s) is released from the nanoparticle only when the polymer matrix is degraded or broken, and then an indicative effect is triggered or enhanced. A nanoparticle-based method for screening a bioactive substance and a microfluidic-based screening system have also been disclosed.

Classes IPC  ?

• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
• C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase

Abrégé

A bioinformatic method is used to analyze, discover and predict, from human intestinal metagenomics, peptides having microorganism inhibiting activity, that is, antimicrobial peptides, and the activity thereof is confirmed by means of experiments. Disclosed are a variety of antimicrobial peptides and a use thereof.

Classes IPC  ?

• A61K 38/03 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
• A61K 38/40 - Transferrines, p. ex. lactoferrines, ovotransferrines
• C07K 4/12 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'animauxPeptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'humains

Abrégé

The present invention relates to an anti-novel coronavirus bispecific antibody and the use thereof. The bispecific antibody of the present invention is obtained by means of modifying novel coronavirus monoclonal antibodies H4 and B38 by virtue of a genetic engineering method, and can also recognize different sites of RBDs in a novel coronavirus S protein. The bispecific antibody has a much higher neutralizing activity against novel-coronavirus pseudoviruses than a maternal monoclonal antibody, and also has a higher inhibitory activity against novel-coronavirus live viruses than same. The bispecific antibody of the present invention improves the selectivity and neutralizing activity compared with the maternal monoclonal antibody, and improves the safety and effectiveness of a monoclonal antibody drug. The bispecific antibody can be used in the preparation of a potential drug for diagnosing, preventing and treating diseases caused by novel coronaviruses, and has huge market value and good application prospects.

Classes IPC  ?

• C07K 16/46 - Immunoglobulines hybrides
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to a β-coronavirus antigen, a β-coronavirus bivalent vaccine, preparation methods therefor, and applications thereof. The amino acid sequence of the β-coronavirus antigen comprises, according to a sequence from an end N to an end C, an amino acid sequence arranged according to a (A-B)-(A'-B') style or an amino acid sequence arranged according to a (A-B)-C-(A'-B') style, wherein A-B represents part of the amino acid sequence or all of the amino acid sequence deriving from a receptor binding domain of a surface spike protein of a β-coronavirus; A'-B' represents part of the amino acid sequence or all of the amino acid sequence deriving from a receptor binding domain of a surface spike protein of another β-coronavirus; C represents connection of the amino acid sequences; and the β-coronavirus antigen is of a single-chain heterodimer structure. By using the β-coronavirus antigen, the β-coronavirus bivalent vaccine is obtained, and the bivalent vaccine can stimulate a mouse to produce a strong antibody response.

Classes IPC  ?

• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

SF162P3SF162P3. Also provided are a preparation method for the anti-HIV polypeptide modified with PEG, and a use of the anti-HIV polypeptide modified with PEG.

Classes IPC  ?

• C07K 14/16 - HIV-1
• C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
• A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV

Abrégé

The present invention falls within the field of the genetic engineering of plants, and provides a method for obtaining wheat with increased resistance to powdery mildew, wherein the wheat has a yield comparable to or even increased with regard to that of the wild type.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• A01H 1/00 - Procédés de modification des génotypes
• A01H 1/02 - Méthodes ou appareils d'hybridationPollinisation artificielle
• A01H 5/00 - Angiospermes, c.-à-d. plantes à fleurs, caractérisées par leurs parties végétalesAngiospermes caractérisées autrement que par leur taxonomie botanique

Abrégé

The present invention relates to an influenza virus neuraminidase inhibitor, a preparation method therefor and an application thereof, which belong to the technical field of pharmaceutical chemistry. The structural general formula of the influenza virus neuraminidase inhibitor is shown in formula I, wherein: m is any natural number selected from 2-11, n is any natural number selected from 3-12, X is selected from OCOO or O; y is selected from formula aa, formula bb and formula cc; R in formula cc is selected from H or formula dd; R' in formula dd is H or a fluorescence labeling group; and Z is any natural number selected from 3-6. The described influenza virus neuraminidase inhibitor has significant inhibitory activity on various influenza viruses, especially on zanamivir-resistant influenza viruses (H3N2, E119V). The water solubility of an original medicine is remarkably improved, the lipid-water distribution coefficient is tens of times higher than that of the original medicine, and the inhibitor can be made into an oral preparation, which is a great breakthrough in pharmaceutical dosage forms.

Classes IPC  ?

• C07J 41/00 - Stéroïdes normaux contenant un ou plusieurs atomes d'azote n'appartenant pas à un hétérocycle
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

The present invention "an anti-influenza virus compound, and a preparation method therefor and an application thereof" relates to the technical field of pharmaceutical chemistry. The anti-influenza virus compound has the following structural general formula: (formula 1), wherein m is any natural number selected from 2-11, n is any natural number selected from 3-12, X is selected from OCOO or O, and Y is selected from (formula 2) or (formula 3). The anti-influenza virus compound of the present invention has significant inhibition activity on various influenza viruses, particularly on zanamivir-resistant influenza viruses (H3N2, E119V), remarkably improves the water solubility of the original medicine, has a lipid/water partition coefficient tens of times higher than that of the original medicine, and can achieve preparation into an oral preparation which is a major breakthrough in medicine dosage forms.

Classes IPC  ?

• C07J 43/00 - Stéroïdes normaux ayant un hétérocycle contenant de l'azote non condensé ou condensé en spiro avec le squelette du cyclopenta[a]hydrophénanthrène
• A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine

Abrégé

Provided are an anti-novel coronavirus monoclonal antibody, and a composition (such as a diagnostic agent and a therapeutic agent) containing the antibody. In addition, also provided is use of the antibody. The antibody can be applied to diagnosis, prevention and/or treatment of novel coronavirus infection and/or diseases caused by the infection (such as novel coronavirus pneumonia).

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention relates to the fields of immunology and molecular virology, in particular, the field of the diagnosis, prevention, and treatment of a novel coronavirus. Specifically, the present invention relates to a monoclonal antibody for resisting a novel coronavirus and a composition containing the antibody (such as a diagnostic agent and a therapeutic agent). In addition, the present invention also relates to the use of the antibody. The antibody can be used for diagnosing, preventing and/or treating infections caused by the novel coronavirus or diseases caused by the infections (such as COVID-19 pneumonia).

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 5/16 - Cellules animales
• C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

Provided in the present invention are a humanized monoclonal antibody for the 2019 novel coronavirus (2019-nCOV) and the use thereof. The antibody is capable of specifically binding with a receptor binding domain (RBD) of 2019-nCOV and blocking the binding between the RBD of 2019-nCOV and ACE2, and furthermore inhibiting the infection caused by 2019-nCOV.

Classes IPC  ?

• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

Provided in the present invention are a humanized monoclonal antibody for the 2019 novel coronavirus (2019-nCOV) and the use thereof. The antibody is capable of specifically binding with a receptor binding domain (RBD) of 2019-nCOV and blocking the binding between the RBD of 2019-nCOV and ACE2, and furthermore inhibiting the infection caused by 2019-nCOV.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C07K 1/00 - Procédés généraux de préparation de peptides
• G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Provided in the present invention are a beta-coronavirus antigen, a preparation method therefor and the use thereof. The amino acid sequence of the beta-coronavirus antigen comprises an amino acid sequence arranged in an (A-B)-(A-B) pattern, or an amino acid sequence arranged in an (A-B)-C-(A-B) pattern, or an amino acid sequence arranged in an (A-B)-(A-B') pattern, or an amino acid sequence arranged in an (A-B)-C-(A-B') pattern, and the beta-coronavirus antigen has a single-chain dimer structure. The single-chain dimer expressed in the embodiment of the present invention is stable in terms of content and has a good immunogenicity as a beta-coronavirus antigen, and a vaccine prepared using the single-chain dimer as a beta-coronavirus antigen can stimulate mice to generate a neutralizing antibody with very high titer.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C12N 15/09 - Technologie d'ADN recombinant
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

A method for preparing a double-arm clamping-type mesh carrying frame. The method sequentially comprises the steps of: first preparing a hard material into a support frame (1) of which two adjacent support frame arms are located on the same plane and are of a clamping structure; then putting the support frame into a molten adhesive liquid to obtain a support frame dipped in the adhesive liquid; and finally retracting the support frame dipped in the adhesive liquid, and waiting for the adhesive liquid to be solidified along the support frame arms into an adhesive layer (2). The present invention further relates to the double-arm clamping-type mesh carrying frame apparatus comprising a support frame and an adhesive layer, wherein the adhesive layer is adhered to the inner side of a clamping structure portion of two adjacent support frame arms of the support frame.

Classes IPC  ?

• G01N 23/2204 - Supports d’échantillons à cet effetMoyens de transport des échantillons à cet effet
• G01N 23/2202 - Préparation d’échantillons à cet effet
• G01N 1/31 - Appareils à cet effet

Abrégé

Disclosed is a magnetic attraction type mesh-carrying frame device. The device comprises a frame body (1), a magnet (2) and a hydrophobic layer (3). According to the device, the outer rings of a plurality of nickel meshes can be attracted onto a frame body (1) at the same time under the action of a magnetic force, so that batch operations, such as rinsing, immunolabeling and dyeing, on the nickel meshes can be realized. In addition, by means of the hydrophobic effect of the hydrophobic layer (3), liquid brought out by the nickel mesh in the continuous replacement process of different liquids can be reduced to almost zero, and compared with the prior art, the probability of cross contamination among reagents is effectively reduced.

Classes IPC  ?

• G01N 23/2204 - Supports d’échantillons à cet effetMoyens de transport des échantillons à cet effet
• G01N 23/2202 - Préparation d’échantillons à cet effet
• G01N 33/532 - Production de composés immunochimiques marqués

Abrégé

The present invention relates to a dual-arm clamping type holder for transmission electron microscopy grids and preparation method thereof. The preparation method comprises: firstly manufacturing a frame with two adjacent arms located on a same plane and have a clamping structure by a hard material; then putting the frame in a molten adhering liquid so that the frame is dipped with the adhering liquid; and finally, taking out the frame dipped with the adhering liquid, and waiting for the adhering liquid to solidify into adhering layers along the arms. The dual-arm clamping type holder manufactured by the method of the present invention comprises a frame and adhering layers; and the adhering layers adhere to the inner sides of the clamping structure between the two adjacent arms of the frame.

Classes IPC  ?

• G01N 1/00 - ÉchantillonnagePréparation des éprouvettes pour la recherche
• G01N 1/28 - Préparation d'échantillons pour l'analyse
• G01N 23/2204 - Supports d’échantillons à cet effetMoyens de transport des échantillons à cet effet
• G01N 23/2202 - Préparation d’échantillons à cet effet
• G01N 1/31 - Appareils à cet effet
• G01N 1/30 - TeintureImprégnation

Abrégé

The present invention relates to a magnetic holder for immunoelectron microscopy grids. The holder comprises a frame, a magnet and a hydrophobic layer. The device can use a magnetic force to simultaneously attach the outer rings of nickel grids to the frame, so that a batch operation (such as rinsing, immunolabeling and dyeing) of the nickel grids can be realized. In addition, due to the hydrophobic effect of the hydrophobic layer, the holder can reduce the amount of the liquid carried by the nickel grids in the process of continuously transferring the nickel grids between different types of liquids to almost zero. Compared with the prior art, the magnetic holder effectively reduces the probability of cross-contamination between reagents.

Classes IPC  ?

• G01N 23/2202 - Préparation d’échantillons à cet effet
• G01N 23/2204 - Supports d’échantillons à cet effetMoyens de transport des échantillons à cet effet
• G01N 33/532 - Production de composés immunochimiques marqués
• G01N 1/28 - Préparation d'échantillons pour l'analyse

Abrégé

141-151141-151 epitope peptide, and an application thereof. The T-cell receptor comprises an α chain and a β chain; the α chain comprises three complementarity determining regions, and the amino acid sequences are respectively as shown at positions 48-53, 71-77, and 112-121 of SEQ ID No. 2; the β chain comprises three complementarity determining regions, and the amino acid sequences are respectively as shown at positions 46-50, 68-73, and 111-122 of SEQ ID No. 4. Experiments show that the T-cell receptor has not only HBV polypeptide epitope-dependent activation and proliferation capabilities, but also good activity to kill target cells in vivo and in vitro, and can also effectively clear the chronic infection with HBV in the body. The present invention has important application value.

Classes IPC  ?

• C07K 14/725 - Récepteurs de lymphocytes-T
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 31/20 - Antiviraux pour le traitement des virus ADN
• A61P 35/00 - Agents anticancéreux

Abrégé

Provided in the present invention are a Zika/dengue vaccine and an application thereof. The present invention introduces a mutation into the E-protein FL fusion region of the Zika virus or dengue virus, antigens with said mutation being unable to bind to antibodies causing ADE. After immunisation with the vaccine of the present invention acquired on the basis of on said antigens, the production of FL epitope-induced antibodies can be prevented, thereby reducing or eliminating the ADE effect.

Classes IPC  ?

• C07K 14/18 - Togaviridae, p. ex. flavivirus, virus de la peste, virus de la fièvre jaune, virus de l'hépatite C, virus de l'encéphalite japonaise
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/40 - Protéines de virus à ARN, p. ex. flavivirus
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

An application of a branched-chain α-ketoacid dehydrogenase complex in preparation of malonyl coenzyme A. A method for preparing malonyl coenzyme A by using the branched-chain α-ketoacid dehydrogenase complex. The method comprises: introducing genes encoding the branched-chain α-ketoacid dehydrogenase complex into biological cells, and expressing the genes encoding the branched-chain α-ketoacid dehydrogenase complex to obtain recombinant cells; culturing the recombinant cells to obtain malonyl coenzyme A. The branched-chain α-ketoacid dehydrogenase complex is a complete-set protein consisting of M1) or M2): M1): bkdF, bkdG, bkdH, and lpdA1; and M2): bkdA, bkdB, bkdC, and lpdA1. Experimental results show that by using the branched-chain α-ketoacid dehydrogenase complex, not only malonyl coenzyme A can be prepared, but also a target product using malonyl coenzyme A as an intermediate product can further be prepared.

Classes IPC  ?

• C12P 19/32 - Nucléotides avec un système cyclique condensé, contenant un cycle à six chaînons, comportant deux atomes d'azote dans le même cycle, p. ex. nucléotides puriques, dinucléotide de la nicotinamide-adénine
• C12P 7/42 - Acides hydroxycarboxyliques
• C12P 13/00 - Préparation de composés organiques contenant de l'azote
• C12P 7/22 - Préparation de composés organiques contenant de l'oxygène contenant un groupe hydroxyle aromatiques
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C12N 9/10 - Transférases (2.)
• C12N 9/88 - Lyases (4.)
• C12R 1/19 - Escherichia coli

Abrégé

Provided is a method for selective hydrazide modification on a C terminus of an enzyme-catalyzed protein. Provided is a method for performing hydrazide modification on a C terminus of a protein, comprising: attaching a glycine to the C terminus of a protein to be modified, amidating the C terminus by means of the catalysis of enzyme 1 (SEQ ID No.1) , and reacting same with nucleophilic organic amines by means of the catalysis of enzyme 2 (SEQ ID No.2), so as to complete the hydrazide modification on the C terminus of the protein. Use of the method may implement the hydrazide modification on the C terminus of the protein. In addition, the reaction is an aqueous reaction, and the conditions are mild. The C terminus is selectively modified, and does not affect other modified groups of a side chain and thus, the side chain does not need to be protected. A substrate spectrum is wide, and there is no substrate protein amino acid sequence restriction.

Classes IPC  ?

• C12N 9/80 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides aliphatiques
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés

Abrégé

Provided is a genome edited fusion polypeptide, with same comprising a CRISPR nuclease domain and a transcription activation domain. Also provided are a polynucleotide and an expression construct encoding the fusion polypeptide, a genome editing system comprising the fusion polypeptide, polynucleotide and/or expression construct, and a method for editing the genome of a cell by means of the genome editing system.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales

Abrégé

A method for improving the production of streptomyces polyketide compounds is provided. The method greatly improves the capability of the streptomyces polyketide compounds by strengthening a triacylglycerol decomposition pathway in streptomyces during the stationary phase. A method for switching the primary metabolism of streptomyces to the secondary metabolism, streptomyces producing polyketide compounds, and use thereof are also provided.

Classes IPC  ?

• C12P 17/18 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles condensés entre eux ou condensés avec un système carbocyclique commun, p. ex. rifamycine
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 15/01 - Préparation de mutants sans introduction de matériel génétique étrangerProcédés de criblage à cet effet
• C12R 1/465 - Streptomyces

Abrégé

The present application discloses in the examples a method for inhibiting bacterial biofilm formation, specifically comprising treating bacteria by using an effective amount of a coumarin-chalcone complex. While inhibiting bacterial biofilm formation, the toxicity of bacteria can be reduced, and use in combination with an antibiotic can enhance the sensitivity of the bacteria to the antibiotic. The present application further discloses in the examples a composition. The composition comprises an effective amount of the coumarin-chalcone complex. The composition can be used for inhibiting bacterial biofilm formation. The composition can also comprises an antibiotic. The minimum bacteriostatic concentration and the minimum biofilm clearance concentration of the antibiotic are reduced when used.

Classes IPC  ?

• A61K 31/37 - Coumarines, p. ex. psoralène
• A61K 31/12 - Cétones
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention relates to a biosensor, composition and kit comprising an allosteric transcription factor and a CRISPR/Cas12a system, and an associated method and use of same. The mechanism of the biosensor is to use a small molecule detection tool mediated by the allosteric transcription factor and the CRISPR/Cas12a, combine a target small molecule and the allosteric transcription factor such that the affinity between the allosteric transcription factor and double-stranded DNA is changed, and use the cis-cleavage activity and/or the trans-cleavage activity on single-stranded DNA of the CRISPR/Cas12a to cleave a dsDNA probe and/or an ssDNA probe so as to convert a signal of the target small molecule into a corresponding optical signal. In the in vitro detection of small molecules, the biosensor, composition and kit, and the associated method of the present invention can not only save on time and cost, but are also highly sensitive and have the potential of high-throughput detection.

Classes IPC  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01N 1/34 - PurificationNettoyage
• C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes

Abrégé

A method for extracting an Indian bread peel composition, comprising: (1) weighing an Indian bread peel sample, adding same to a soaking solvent for soaking, reflowing, and collecting a filtrate; (2) performing vacuum concentration and drying to obtain a crude extract; (3) suspending the crude extract into 1 mol/L NaOH aqueous solution, performing ultrasound for 1 h, and filtering to obtain a crude precipitate; (4) suspending the crude precipitate in water, adding acetic acid for neutralizing until pH is equal to 7, and filtering to obtain a precipitate; and (5) reflowing the precipitate by means of a recrystallization solvent to form a thermal saturation solution, and recrystallizing same to obtain the Indian bread peel composition. The beneficial effect is that: the composition is rich in the content in the Indian bread peel, and can be rapidly prepared. At the same time, the composition has a good application prospect in the preparation of a drug or food for treating diabetes, hyperlipidemia, obesity, and non-alcoholic fatty liver diseases.

Classes IPC  ?

• A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• A61P 3/06 - Antihyperlipémiants
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline

Abrégé

A nanoparticle comprises water-insoluble polymer matrix and an indicator constituent(s), wherein the indicator constituent(s) is released from the nanoparticle only when the polymer matrix is degraded or broken, and then an indicative effect is triggered or enhanced. A nanoparticle-based method for screening a bioactive substance and a microfluidic-based screening system have also been disclosed.

Classes IPC  ?

• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase

Abrégé

Provided is a method for construction of recombinant bacteria for producing 3-hydroxypropionic acid. The method includes: knocking out fadR, fabF and fabH genes of recipient bacteria, introducing acc genes or gene clusters, alKL and Mcr genes, and enhancing the expression of fadL, fadD, sthA genes and atoSC gene clusters in the recipient bacteria. Also provided is a method for producing 3-hydroxypropionic acid by using the recombinant bacteria.

Classes IPC  ?

• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12P 7/52 - Acide propioniqueAcides butyriques
• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C12N 9/10 - Transférases (2.)
• C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora
• C12N 1/20 - BactériesLeurs milieux de culture
• C12R 1/19 - Escherichia coli

Abrégé

Provided in the present invention are an anti-CD47 monoclonal antibody and an antigen binding fragment thereof, which are capable of specifically binding to CD47 molecules, which can, after binding, block the binding of CD47 to SIRPα, and which can produce a series of biological effects.

Classes IPC  ?

• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• C12N 15/12 - Gènes codant pour des protéines animales
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention discloses a method for modifying an amino acid attenuator, a class of amino acid attenuator mutants, engineered bacteria created on the basis of the amino acid attenuator mutants, and use of the engineered bacteria. The present invention protects a method for relieving the attenuation regulation of an amino acid operon gene, which is modification of the amino acid operon gene by: removing a gene coding for a leader peptide and an anterior reverse complementary palindromic sequence in the terminator stem-loop structure, and maintaining a posterior reverse complementary palindromic sequence in the terminator. The amino acid operon particularly can be histidine operon, tryptophan operon, phenylalanine operon, alanine operon, threonine operon and etc. The present invention can be used for the production of amino acids and derivatives thereof in fermentation by bacteria, providing a novel method for improving the production of amino acids in fermentation.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12P 13/06 - AlanineLeucineIsoleucineSérineHomosérine
• C12P 13/22 - TryptophaneTyrosinePhénylalanineDihydroxy-3, 4 phénylalanine

Abrégé

A transgenic method of obtaining blue flowers by catalyzing glutamine to synthesize indigo is provided. The steps thereof comprise: 1) respectively cloning a Sfp gene encoding phosphopantetheinyl transferase and a bpsA gene encoding indigo synthase downstream of a plant promoter in a plant-promoter-containing plasmid; 2) amplifying the obtained plasmid in E. coli and then transferring the same to Agrobacterium tumefaciens; and 3) transferring DNA containing Sfp and bpsA into a plant. The blue flowers produced by the present invention have various characteristics of natural flowers, being fresh, flower-scented, non- color-fading, and non-toxic. The transgene-encoded enzyme and the produced indigo are not in the vacuole and are not affected by the low pH of the plant vacuole, thereby resulting in a pure blue color. The precursor of the blue matter, i.e., the substrate of the enzyme, is glutamine, which is abundant in plants. The enzyme catalysis reaction comprises a single step, and the transgenic transformation can be carried out on natural white flowers.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• C12N 15/60 - Lyases (4)
• C12N 15/54 - Transférases (2)
• A01H 5/00 - Angiospermes, c.-à-d. plantes à fleurs, caractérisées par leurs parties végétalesAngiospermes caractérisées autrement que par leur taxonomie botanique
• A01H 6/56 - Liliaceae, p. ex. Alstroemeria ou Lilium
• A01H 6/74 - Rosaceae, p. ex. fraise, pomme, amande, poire, rose, mûre ou framboise
• A01H 6/30 - Caryophyllaceae
• A01H 6/62 - Orchidaceae [famille des orchidées]

Abrégé

Disclosed are a chimpanzee adenovirus vector-based zika virus vaccine and a preparation method therefor, belonging to the fields of biotechnology and virology. A chimpanzee adenovirus AdC7 is constructed as a replication defective recombinant expression vector. The vector has good immunogenicity and genetic stability, and a novel zika virus vaccine is prepared on the basis of the vector. Neutralizing antibodies against zika virus are effectively induced in mice which have been immunised with the vaccine, thereby protecting the mice from being infected, and also protecting the tissues and organs of the mice from being damaged.

Classes IPC  ?

• C12N 15/861 - Vecteurs adénoviraux
• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• A61K 39/12 - Antigènes viraux
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Disclosed is a limited-replication-type mucosal vaccine for influenza viruses. First, a mutein is provided by mutating the following two amino acid residues of an NS1 protein of influenza virus: the amino acid residue at position 38 is mutated from arginine to alanine, and the amino acid residue at position 41 is mutated from lysine to alanine. A recombinant virus is also provided. The recombinant virus is obtained by mutating two codons encoding amino acid residues of the NS1 protein in the influenza virus genome, in which the codon of the amino acid residue at position 38 from N-terminus is mutated from an arginine codon to an alanine codon, and the codon of the amino acid residue at position 41 from the N-terminus is mutated from a lysine codon to an alanine codon. The use of any of the recombinant viruses described above for the preparation of influenza virus vaccines is also disclosed.

Classes IPC  ?

• C07K 14/11 - Orthomyxoviridae, p. ex. virus de l'influenza
• C12N 15/44 - Orthomyxoviridae, p. ex. virus de l'influenza
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

A recombinant bacterium for producing L-lysine, a construction method thereof, and a method for producing L-lysine by using the recombinant bacterium. The recombinant bacterium has increased expression and/or activity of asparaginase compared to a starting bacterium.

Classes IPC  ?

• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
• C12N 15/69 - Augmentation du nombre de copies du vecteur
• C12P 13/08 - LysineAcide diaminopiméliqueThréonineValine

Abrégé

A recombinant bacterium for producing L-lysine, a construction method thereof, and a method for producing L-lysine by using the recombinant bacterium. The recombinant bacterium has increased expression and/or activity of asparaginase compared to a starting bacterium.

Classes IPC  ?

• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12P 13/08 - LysineAcide diaminopiméliqueThréonineValine
• C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
• C12N 15/69 - Augmentation du nombre de copies du vecteur
• C12R 1/01 - Bactéries ou actinomycètes
• C12R 1/645 - Champignons

Abrégé

A recombinant virus is obtained by mutating a codon that encodes a tyrosine residue at position 385 of NP protein in the genome of influenza A virus to a codon of phenylalanine residue. The virus WSN-Y385F is a temperature-sensitive virus that can normally replicate and survive at 37° C., and cannot normally replicate and cannot survive at 33° C. Phosphorylation of a NP protein of influenza A virus can be inhibited by mutating an amino acid residue at position 385 from N terminal of the NP protein of influenza A virus, from a tyrosine to a phenylalanine. The recombinant virus can be used in analyzing mechanisms of infection by influenza virus, and in connection with methods of prevention and treatment of infection by influenza virus.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

Provided are key amino acid sites regulating the nuclear export of a nucleoprotein in influenza A and B viruses and the use thereof as anti-influenza virus drug targets. Also provided is a pharmaceutical composition for treating the influenza A or B virus infection, comprising a compound that regulates the nuclear export of a nucleoprotein in the influenza A or B virus.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

Provided is a method for construction of recombinant bacteria for producing 3-hydroxy propionic acid. The method comprises: knocking out fadR, fabF and fabH genes of receptor bacteria, introducing acc genes or gene clusters, alKL and Mcr genes, and enhancing the expression of fadL, fadD, sthA genes and atoSC gene clusters in the receptor bacteria. Also provided is a method for producing 3-hydroxy propionic acid by using the recombinant bacteria.

Classes IPC  ?

• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora
• C12P 7/18 - Polyols
• C12R 1/19 - Escherichia coli

Abrégé

Provided is a recombinant virus, the recombinant virus being obtained by mutating a codon, which encodes a tyrosine residue at position 385 of an NP protein in a genome of type A influenza virus, into a codon of a phenylalanine residue. Also provided is a method for inhibiting the phosphorylation of the NP protein of the type A influenza virus, wherein the NP protein of the type A influenza virus is mutated from tyrosine to phenylalanine at an amino acid residue at a position 385 of an N-terminus.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C07K 14/11 - Orthomyxoviridae, p. ex. virus de l'influenza
• C12N 15/44 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

Disclosed is a method for modifying an amino acid attenuator, a type of amino acid attenuator mutants, engineered bacteria generated on the basis of the amino acid attenuator mutants, and use of the engineered bacteria. Further disclosed is a method for relieving the attenuation regulation of an amino acid operon gene. The amino acid operon gene is modified as follows: removing a gene coding for a leader peptide and an anterior reverse complementary palindromic sequence in the terminator stem-loop structure, and maintaining a posterior reverse complementary palindromic sequence in the terminator. The amino acid operon can be selected from histidine operon, tryptophan operon, phenylalanine operon, alanine operon, and threonine operon.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12P 13/06 - AlanineLeucineIsoleucineSérineHomosérine
• C12P 13/22 - TryptophaneTyrosinePhénylalanineDihydroxy-3, 4 phénylalanine
• C12R 1/19 - Escherichia coli

Abrégé

The invention provides a polypeptide capable of using 4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) as a substrate to produce isoprene, a nucleic acid encoding the polypeptide, and a vector and a cell comprising the nucleic acid. In addition, the invention also provides a method for producing isoprene using the polypeptide, and a method for preparing the polypeptide.

Classes IPC  ?

• C12N 9/88 - Lyases (4.)
• C07K 14/32 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Bacillus (G)
• C12P 5/00 - Préparation des hydrocarbures
• C12P 5/02 - Préparation des hydrocarbures acycliques

Abrégé

Pseudomonas species, suggesting the great potential of PsIG in clinical and environmental fields.

Classes IPC  ?

• A01N 63/02 - Substances produites par, ou obtenues à partir de micro-organismes ou d'animaux
• A01N 43/60 - Diazines-1,4Diazines-1,4 hydrogénées
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A01N 37/46 - Dérivés N-acylés

Abrégé

A humanized monoclonal antibody for Zika virus, and applications thereof, related to the technical field of medicine. Using Zika E protein expressed by E. coli as an antigen, selecting from PBMCs of a convalescing Zika patient a memory B cell capable of specifically binding to Zika E protein by means of flow sorting, then performing RT-PCR on the single selected B cell, obtaining a sequence and fragment of a variable region of the antibody, and further connecting same with a constant region into an expression vector. After expression by a mammalian cell and purification, performing a series of function tests, comprising detecting bonding strength with ZIKV-E protein, in vitro neutralization results, in vivo protection ability, etc., obtaining three strains of humanized monoclonal antibody having complete protection from Zika virus infection.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C12N 15/13 - Immunoglobulines
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

The invention provides a use of aromatic farnesyl compounds and pharmaceutical salts thereof in the preparation of slimming medicaments, slimming foods, slimming drinks and slimming health products.

Classes IPC  ?

• A61K 31/365 - Lactones
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• A23L 2/40 - Compositions effervescentes
• A23L 2/395 - Compositions sèches sous une forme ou une présentation particulières
• A23L 31/00 - Extraits ou préparations comestibles de champignonsLeur préparation ou leur traitement
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs